<DOC>
	<DOCNO>NCT00837785</DOCNO>
	<brief_summary>To establish pharmacokinetic ( PK ) profile BG00012 , measure primary metabolite , monomethyl fumarate ( MMF ) , 24-hour dosing period subject relapsing-remitting multiple sclerosis ( RRMS ) , variety baseline demographic characteristic .</brief_summary>
	<brief_title>A 24-Hour Pharmacokinetic Determination BG00012 After Single-Day Oral Administration Subjects With MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>1 . Aged 18 55 year old , inclusive , time informed consent . 2 . Have confirm diagnosis RRMS accord McDonald criterion # 14 . 3 . Be ambulatory . 1 . Primary progressive , secondary progressive , progressiverelapsing multiple sclerosis ( PRMS ) . 2 . History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic ( MS ) , dermatologic , psychiatric , renal , oncologic , anaphylaxis major disease , determine Investigator . 3 . Current enrollment drug , biologic , device study treatment another investigational drug within 6 month 5 halflives investigational product , whichever time period longer . 4 . Serious infection ( e.g. , pneumonia , septicemia ) within 2 month prior Day 1 . 5 . Pregnant nursing woman . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>